Spyre Therapeutics, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   SKYLINE-LTE · Long-acting Antibodies Alone and in Combinations…SKYLINE-LTE · Long-acting Antibodies Alone and in Combinations for IBD

   Trial sites expanded: 59 → 70 locations

   And 2 more changes in the last 30 days

   Spyre Therapeutics, Inc.·Phase 2· NCT07652294· Registry history of NCT07652294 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

2. Minor

   SKYLINE-UC · Long-acting Antibodies Alone and in Combinations for…SKYLINE-UC · Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

   Trial sites expanded: 267 → 271 locations

   Spyre Therapeutics, Inc.·Phase 2· NCT07012395· Registry history of NCT07012395 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.